ClinicalTrials.gg
CompletedNCT03069352Updated Oct 16, 2026Results posted

A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

A Phase 3 interventional study of Placebo and Venetoclax in Acute Myeloid Leukemia (AML), sponsored by AbbVie. Completed at 109 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Updated Oct 16, 2026Study documents postedPosted results revised+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
211
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 202 studies testing venetoclax in Leukemia, Myeloid, Acute — 116 open to participants now, 144 under way, 21 of them phase 3. venetoclax · Leukemia, Myeloid, Acute.

Enrollment
26th of 202
211 · median 57
Started
2017
with 6 others
Phase 3
16 of 202
7 open now
Registered
11th of 202
by date
Lead sponsor
15 of 202
AbbVie

Among the 202 studies testing venetoclax in Leukemia, Myeloid, Acute, this one is the 26th largest by enrollment, is one of 7 that started in 2017, is one of 16 in phase 3, and was the 11th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 816 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

116 of the 202 studies testing venetoclax in Leukemia, Myeloid, Acute are open now, in 12 countries. Recruiting first, the newest first:

111 more — sign in →

By country, each count listing its studies:

All 116 open studies →

About venetoclax

venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 202 studies testing venetoclax in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate if venetoclax when co administered with low-dose cytarabine (LDAC) improves overall survival (OS) versus LDAC and placebo, in treatment-naïve patients with acute myeloid leukemia (AML).

Read the detailed description

Acute myeloid leukemia (AML) is an aggressive and rare cancer of myeloid cells (a white blood cell responsible for fighting infections). Successful treatment of AML is dependent on what subtype of AML the patient has, and the age of the patient when diagnosed.

Venetoclax is an experimental drug that kills cancer cells by blocking a protein (part of a cell) that allows cancer cells to stay alive. This study is designed to see if adding venetoclax to cytarabine works better than cytarabine on its own.

This is a Phase 3, randomized, double-blind (treatment unknown to patients and doctors), placebo-controlled, multicenter study in patients with AML who are 18 or more years old and have not been treated before. Patients who take part in this study should not be suitable for intensive induction chemotherapy (usual starting treatment). Abbvie is funding this study which will take place at approximately 125 hospitals globally. In this study, 2/3 of patients will receive venetoclax every day with cytarabine and the remaining 1/3 will receive placebo (dummy) tablets with cytarabine.

Participants will continue to have study visits and receive treatment for as long as they are having a clinical benefit. The effect of the treatment on AML will be checked by taking blood, bone marrow, scans, measuring side effects and by completing health questionnaires. Blood and bone marrow tests will be completed to see why some people respond better than others.

03

Conditions studied

  • Acute Myeloid Leukemia (AML)

Keywords

  • Acute Myeloid Leukemia
  • Leukemia
  • Treatment naïve
  • Venetoclax
  • Cytarabine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant must have histological confirmation of acute myeloid leukemia (AML) by World Health Organization criteria, be ineligible for intensive induction chemotherapy and either be:

    • ≥ 75 years of age OR
    • ≥ 18 to 74 years of age and fulfill at least one criteria associated with lack of fitness for intensive induction chemotherapy:

      • (ECOG) performance status of 2 - 3
      • Cardiac history of congestive heart failure (CHF) requiring treatment or ≤ 50% or chronic stable angina
      • Diffusing capacity of the lung for carbon monoxide (DLCO) ≤ 65% or (FEV1) ≤ 65%
      • ≥ 30 mL/min to \< 45 ml/min
      • Moderate hepatic impairment with total > 1.5 to ≤ 3.0 × (ULN)
      • Other comorbidity that the physician judges to be incompatible with conventional intensive chemotherapy which must be reviewed and approved by the study medical monitor before study enrollment
  2. Participant must have an ECOG performance status:

    • of 0 to 2 for subjects ≥ 75 years of age OR
    • of 0 to 3 for subjects between 18 to 74 years of age
  3. Participant must have a projected of at least 12 weeks.
  4. Participant must have adequate renal function as demonstrated by a creatinine clearance ≥ 30 mL/min; calculated by the Cockcroft Gault formula or measured by 24-hour urine collection.
  5. Participant must have adequate liver function as demonstrated by:

    • (AST) ≤ 3.0 × ULN*
    • alanine aminotransferase (ALT) ≤ 3.0 × ULN*
    • bilirubin ≤ 1.5 × ULN*

      • Subjects who are \< 75 years of age may have bilirubin of ≤ 3.0 × ULN

    (*Unless considered to be due to leukemic organ involvement.)

  6. Female participants must be either defined as:

    • Age > 55 years with no menses for 12 or more months without an alternative medical cause.
    • Age ≤ 55 years with no menses for 12 or more months without an alternative medical cause AND a follicle-stimulating hormone (FSH) level > 40 IU/L.

    OR

    • Permanently surgical sterile (bilateral oophorectomy, bilateral salpingectomy or hysterectomy).

    OR

    • A woman of (WOCBP) practicing at least one protocol specified method of starting at Study Day 1 through at least 180 days after the last dose of study drug.
  7. Male participants who are sexually active, must agree, from Study Day 1 through at least 180 days after the last dose of study drug, to practice protocol specified methods of contraception. Male subjects must agree to refrain from sperm donation from initial study drug administration through at least 180 days after the last dose of study drug.
  8. Females of childbearing potential must have negative results for pregnancy test performed:

    • At Screening with a serum sample obtained within 14 days prior to the first study drug administration, and
    • Prior to dosing with urine sample obtained on Cycle 1 Day 1, if it has been > 7 days since obtaining the serum pregnancy test results.
    • Subjects with borderline pregnancy tests at Screening must have a serum pregnancy test ≥ 3 days later to document continued lack of a positive result.
  9. Participant must voluntarily sign and date an form, approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of any screening or study-specific procedures.

Exclusion criteria

Exclusion Criteria:

  1. Participant has received any prior treatment for AML with the exception of hydroxyurea, allowed through the first cycle of study treatment. Note: Prior treatment for myelodysplastic syndrome is allowed except for use of cytarabine.
  2. Participant had an antecedent myeloproliferative neoplasm (MPN) including myelofibrosis, essential thrombocytosis, polycythemia vera, or chronic myelogenous leukemia (CML) with or without BCR-ABL 1 translocation and AML with BCR-ABL 1 translocation.
  3. Participants that have acute promyelocytic leukemia (APL).
  4. Participant has known central nervous system (CNS) involvement with AML.
  5. Participant has known (HIV) infection (due to potential drug-drug interactions between antiretroviral medications and venetoclax). HIV testing will be performed at Screening, if required per local guidelines or institutional standards.
  6. Participant is known to be positive for virus (HBV), or virus (HCV) infection. Inactive hepatitis carrier status or low viral hepatitis titer on antivirals (non-exclusionary medications) are not excluded.
  7. Participant has received strong or moderate cytochrome P450 3A4 () inducers 7 days prior to the initiation of study treatment.

    • Chinese subjects are excluded from receiving strong and/or moderate CYP3A inhibitors 7 days prior to the initiation of study treatment through the end of intensive pharmacokinetic (PK) collection (24 hours post dose on Cycle 1 Day 10).
  8. Participant has consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges) or star fruit within 3 days prior to the initiation of study treatment.
  9. Participant has cardiovascular disability status of Class > 2. Class 2 is defined as cardiac disease which subjects are comfortable at rest but ordinary physical activity results in fatigue, palpitations, dyspnea, or angina pain. Class 3 is defined as cardiac disease which subjects are comfortable at rest but less than ordinary activity causes fatigue, palpitation, or dyspnea. Class 4 is defined as cardiac disease which subjects have an inability to carry on any physical activity without discomfort, symptoms of heart failure at rest, and if any physical activity is undertaken then discomfort increases.
  10. Participant has chronic respiratory disease that requires continuous oxygen, or significant history of renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, hepatic, cardiovascular disease, any other medical condition or known to any of the study medications including of LDAC that in the opinion of the investigator would adversely affect his/her participating in this study.
  11. Participant has a malabsorption syndrome or other condition that precludes enteral route of administration.
  12. Participant exhibits evidence of other uncontrolled systemic infection requiring therapy (viral, bacterial or fungal).
  13. Participant has a history of other prior to study entry, with the exception of:

    • Adequately treated in situ carcinoma of the cervix uteri or carcinoma in situ of breast;
    • Basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin;
    • Previous malignancy confined and surgically resected (or treated with other modalities) with curative intent.
  14. Participant has a white blood cell count > 25 × 10\^9/L. (Note: hydroxyurea administration or leukapheresis is permitted to meet this criterion).
  15. Previous treatment with venetoclax and/or current participation in any other research study with products.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
211 participants (actual)

Study arms

  • Experimental
    Venetoclax + Low Dose Cytarabine (LDAC)

    Venetoclax 600 mg orally every day (QD) plus LDAC 20 mg/m² subcutaneously on Days 1 to 10 of each 28-day cycle.

    Drug: Venetoclax · Drug: Cytarabine

  • Placebo comparator
    Placebo + LDAC

    Matching placebo to venetoclax orally QD plus LDAC 20 mg/m² subcutaneously on Days 1 to 10 of each 28-day cycle.

    Drug: Placebo · Drug: Cytarabine

Interventions

  • DrugPlacebo

    tablet

  • tablet

    Also known as: ABT-199, Venclexta

  • Subcutaneous injection

    Also known as: Cytosar-U, Ara-C, Arabinosylcytosine

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    Overall survival is defined as the time from the date of randomization to the date of death. Participants who had not died were censored at the date they were last known to be alive on or before the cutoff date. Overall survival was analyzed using Kaplan-Meier methodology.

    Time frame: From randomization until the primary analysis cut-off date of February 15 2019; the median follow-up time was 12.0 months (range: 0.2-17.0) in the placebo arm and 12.0 months (range: 0.1-17.6) in the venetoclax arm.

Secondary outcomes

  1. Percentage of Participants With Complete Remission or Complete Remission With Incomplete Blood Count Recovery (CR + CRi)

    The composite complete remission rate is defined as the percentage of participants with complete remission (CR) or complete remission with incomplete blood count recovery (CRi) at any time during the study as assessed by the investigator. Response was based on physical examination, bone marrow results and hematology values according to the revised guidelines by the International Working Group (IWG) for AML: CR: No morphologic evidence of AML and absolute neutrophil count (ANC) ≥ 10³/μL (1,000/μL), platelets ≥ 10⁵/μL (100,000/μL), red blood cell (RBC) transfusion independence, and bone marrow with \< 5% blasts, absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease. CRi: All criteria as CR except for residual neutropenia \< 10³/μL or thrombocytopenia \< 10⁵/μL. If all criteria for CR are met except RBC transfusion independence, the CRi criteria are met. Participants who had no IWG disease assessments were considered to be non-responders.

    Time frame: Response was assessed at the end of Cycle 1 and every 3 cycles thereafter to the end of treatment. Median treatment duration at the 15 August 2019 cut-off date was 1.7 months (range: 0.1-20.2) and 4.1 months (range: 0.0-23.5) in each group respectively.

  2. Percentage of Participants With Complete Remission or Complete Remission With Partial Hematologic Recovery (CR + CRh)

    The percentage of participants who achieved a complete remission (CR) or complete remission with partial hematologic recovery (CRh) at any time point during the study assessed by the investigator. CR is defined according to the revised guidelines by the IWG for AML as no morphologic evidence of AML, ANC count ≥ 10³/μL, platelets ≥ 10⁵/μL, RBC transfusion independence, and bone marrow with \< 5% blasts, absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease. CRh is a derived response based on bone marrow blast and hematology lab values, achieved when the following criteria are met: * Bone marrow with \< 5% blasts and * Peripheral blood neutrophil count of \> 0.5 × 10³/μL and * Peripheral blood platelet count of \> 0.5 × 10⁵/μL and * A 1 week platelet transfusion-free period prior to the hematology lab collection. Participants with no disease assessments were considered to be non-responders.

    Time frame: Response was assessed at the end of Cycle 1 and every 3 cycles thereafter to the end of treatment. Median treatment duration at the 15 August 2019 cut-off date was 1.7 months (range: 0.1-20.2) and 4.1 months (range: 0.0-23.5) in each group respectively.

  3. Percentage of Participants With Complete Remission or Complete Remission With Incomplete Blood Count Recovery (CR + CRi) by Initiation of Cycle 2

    The composite complete remission rate is defined as the percentage of participants with complete remission (CR) or complete remission with incomplete blood count recovery (CRi) before initiation of Cycle 2, assessed by the investigator. Response was based on physical examination, bone marrow results and hematology values according to the revised guidelines by the IWG for AML: CR: No morphologic evidence of AML and absolute neutrophil count ≥ 10³/μL, platelets ≥ 10⁵/μL, red cell transfusion independence, and bone marrow with \< 5% blasts, absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease. CRi: All criteria as CR except for residual neutropenia \< 10³/μL or thrombocytopenia \< 10⁵/μL. If all criteria for CR are met except for RBC transfusion independence, CRi criteria are met. Participants who had no IWG disease assessments were considered to be non-responders.

    Time frame: Cycle 1, 28 days

  4. Percentage of Participants With Complete Remission and Complete Remission With Partial Hematologic Recovery (CR + CRh) by Initiation of Cycle 2

    The percentage of participants who achieved a complete remission (CR) or complete remission with partial hematologic recovery (CRh) before initiation of Cycle 2 assessed by the investigator. CR is defined according to the revised guidelines by the IWG for AML as no morphologic evidence of AML, ANC count ≥ 10³/μL, platelets ≥ 10⁵/μL, RBC transfusion independence, and bone marrow with \< 5% blasts, absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease. CRh is a derived response based on bone marrow blast and hematology lab values, achieved when when the following criteria are met: * Bone marrow with \< 5% blasts and * Peripheral blood neutrophil count of \> 0.5 × 10³/μL and * Peripheral blood platelet count of \> 0.5 × 10⁵/μL and * A 1-week platelet transfusion-free period prior to the hematology lab collection. Participants with no disease assessments were considered to be non-responders.

    Time frame: Cycle 1, 28 days

  5. Percentage of Participants With Complete Remission

    The complete remission rate is defined as the percentage of participants with complete remission (CR) at any time during the study as assessed by the investigator. Response was based on physical examination, bone marrow results and hematology values according to the revised guidelines by the International Working Group (IWG) for AML. CR is defined as no morphologic evidence of AML and absolute neutrophil count ≥ 10³/μL, platelets ≥ 10⁵/μL, red blood cell transfusion independence, and bone marrow with \< 5% blasts, absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease. Participants who had no IWG disease assessments were considered to be non-responders.

    Time frame: Response was assessed at the end of Cycle 1 and every 3 cycles thereafter to the end of treatment. Median treatment duration at the 15 August 2019 cut-off date was 1.7 months (range: 0.1-20.2) and 4.1 months (range: 0.0-23.5) in each group respectively.

  6. Change From Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue Short Form (SF) 7a

    PROMIS Fatigue SF 7a is a seven-item questionnaire that assesses the impact and experience of fatigue over the past 7 days. All questions employ the following five response options: 1 = Never, 2 = Rarely, 3 = Sometimes, 4 = Often, and 5 = Always. The PROMIS Fatigue 7a score is calculated as a T-score, which is a standardized score with a mean of 50 (based on the average for the United States general population) and a standard deviation (SD) of 10. Higher scores indicate higher levels of fatigue. A decrease in score (negative change from Baseline) indicates improvement in fatigue; the minimum important difference used in this study was 3 points.

    Time frame: Baseline and Day 1 of Cycles 3, 5, 7, 9, and 11

  7. Change From Baseline in Global Health Status/Quality of Life

    The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core (EORTC QLQ-C30) consists of a Global Health Status/Quality of Life (GHS/QoL) scale, a Financial Difficulties scale, 5 functional scales (Cognitive, Social, Physical, Emotional, and Role Functioning), and 8 symptom scales/items (Fatigue, Insomnia, Appetite Loss, Pain, Constipation, Diarrhea, Dyspnea, and Nausea and Vomiting). The GHS/QoL scale includes 2 questions in which participants were asked to rate their overall health and overall quality of life during the past week on a scale from 1 (very poor) to 7 (excellent). The 2 scores were averaged and transformed to a scale from 0 to 100, where a high score represents a high QoL. A positive change from baseline indicates better quality of life.

    Time frame: Baseline and Day 1 of Cycles 3, 5, 7, 9, and 11

  8. Event-free Survival (EFS)

    Event-free survival is defined as the time from randomization to the date of progressive disease (PD), confirmed morphologic relapse from CR or CRi, treatment failure (failure to achieve CR, CRi or morphologic leukemia free state (MLFS) after at least 6 cycles of study treatment), or death from any cause, assessed by the investigator according to the modified IWG criteria. PD: * \> 50% increase in marrow blasts (minimum 15% increase required if blasts \< 30% at baseline); or persistent marrow blast \> 70% for ≥ 3 months; without at least a 100% improvement in ANC to an absolute level \> 0.5 × 10⁹/L, and/or platelets to \> 50 × 10⁹/L non-transfused; or * 50% increase in peripheral blasts to \> 25 × 10⁹/L; or * New extramedullary disease Participants with no events prior to the cut-off date were censored at their last assessment date; participants with no events prior to post-treatment therapy initiated before the cut-off date were censored on the start date of post-treatment therapy.

    Time frame: From randomization until the analysis cut-off date of August 15, 2019; the median follow-up time was 17.7 months (range: 0.2 to 20.8) in the placebo arm and 17.5 months (range: 0.1 to 23.5) in the venetoclax arm.

  9. Percentage of Participants With Post Baseline Red Blood Cell (RBC) Transfusion Independence

    The post baseline red blood cell (RBC) transfusion independence rate was calculated as the percentage of participants who achieved RBC transfusion independence post baseline. RBC transfusion independence is defined as a period of at least 56 consecutive days with no RBC transfusion after the first dose of study drug and on or before the last dose of study drug plus 30 days, or disease progression, or confirmed morphological relapse, or death, or the data cut-off date, whichever occurred earlier.

    Time frame: From first dose of study drug until 30 days after last dose up to the data cut-off date of 15 August 2019; Median time on treatment was 1.7 months (range: 0.1-20.2) in the placebo arm and 4.1 months (range: 0.0-23.5) in the venetoclax arm.

  10. Percentage of Participants With Post Baseline Platelet Transfusion Independence

    The post baseline platelet transfusion independence rate was calculated as the percentage of participants who achieved platelet transfusion independence post Baseline. Platelet transfusion independence is defined as a period of at least 56 consecutive days with no platelet transfusion after the first dose of study drug and on or before the last dose of study drug plus 30 days, or disease progression, or confirmed morphological relapse, or death, or the data cut--off date, whichever occurred earlier.

    Time frame: From first dose of study drug until 30 days after last dose up to the data cut-off date of 15 August 2019; Median time on treatment was 1.7 months (range: 0.1-20.2) in the placebo arm and 4.1 months (range: 0.0-23.5) in the venetoclax arm.

  11. Percentage of Participants With RBC Transfusion Independence Among Those Who Were Transfusion Dependent at Baseline

    The rate of conversion was calculated as the percentage of participants who were post-baseline RBC transfusion independent among participants who had an RBC transfusion within 8 weeks prior to the first dose of study drug (i.e. were transfusion dependent at Baseline). RBC transfusion independence is defined as a period of at least 56 days with no RBC transfusion after the first dose of study drug and on or before the last dose of study drug plus 30 days, or disease progression, or confirmed morphological relapse, or death, or the data cut-off date, whichever occurred earlier.

    Time frame: From first dose of study drug until 30 days after last dose up to the data cut-off date of 15 August 2019; Median time on treatment was 1.7 months (range: 0.1-20.2) in the placebo arm and 4.1 months (range: 0.0-23.5) in the venetoclax arm.

  12. Percentage of Participants With Platelet Transfusion Independence Among Those Who Were Transfusion Dependent at Baseline

    The rate of conversion was calculated as the percentage of participants who were post-baseline platelet transfusion independent among participants who had a platelet transfusion within 8 weeks prior to the first dose of study drug (i.e. were transfusion dependent at Baseline). Platelet transfusion independence is defined as a period of at least 56 days with no platelet transfusion after the first dose of study drug and on or before the last dose of study drug plus 30 days, or disease progression, or confirmed morphological relapse, or death, or the data cut-off date, whichever occurred earlier.

    Time frame: From first dose of study drug until 30 days after last dose up to the data cut-off date of 15 August 2019; Median time on treatment was 1.7 months (range: 0.1-20.2) in the placebo arm and 4.1 months (range: 0.0-23.5) in the venetoclax arm.

  13. Percentage of Participants With Complete Remission or Complete Remission With Incomplete Blood Count Recovery (CR + CRi) and Minimal Residual Disease (MRD) Response

    The percentage of participants with complete remission or complete remission with incomplete blood count recovery AND minimal residual disease (MRD) as assessed by the investigator. Response was based on the modified IWG response criteria for AML: CR: No morphologic evidence of AML and ANC ≥ 10³/μL, platelets ≥ 10⁵/μL, red blood cell (RBC) transfusion independence, and bone marrow with \< 5% blasts, absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease. CRi: All criteria as CR except for residual neutropenia \< 10³/μL or thrombocytopenia \< 10⁵/μL. If all criteria for CR are met except RBC transfusion independence, CRi criteria are met. MRD response (at lowest-point MRD value) was defined as having less than 10-³ residual blasts per leukocyte measured in the bone marrow, per European LeukemiaNet (ELN) recommendations. Participants who had no disease or MRD assessments were considered to be non-responders.

    Time frame: Response was assessed at the end of Cycle 1 and every 3 cycles thereafter to the end of treatment. Median treatment duration at the 15 August 2019 cut-off date was 1.7 months (range: 0.1-20.2) and 4.1 months (range: 0.0-23.5) in each group respectively.

  14. Percentage of Participants With Complete Remission or Complete Remission With Partial Hematologic Recovery (CR + CRh) and Minimal Residual Disease (MRD) Response

    The percentage of participants with complete remission or complete remission with partial hematologic recovery (CRh) AND MRD response as assessed by the investigator. CR is defined according to the modified IWG response criteria for AML as no morphologic evidence of AML, ANC ≥ 10³/μL, platelets ≥ 10⁵/μL, RBC transfusion independence, and bone marrow with \< 5% blasts, absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease. CRh is achieved when the following criteria are met: * Bone marrow with \< 5% blasts and * Peripheral blood neutrophil count of \> 0.5 × 10³/μL and * Peripheral blood platelet count of \> 0.5 × 10⁵/μL and * A 1 week platelet transfusion-free period prior to the hematology lab collection. MRD response (at lowest-point MRD value) was defined as less than 10-³ residual blasts per leukocyte measured in the bone marrow, per ELN recommendations. Participants who had no disease or MRD assessments were considered to be non-responders.

    Time frame: Response was assessed at the end of Cycle 1 and every 3 cycles thereafter to the end of treatment. Median treatment duration at the 15 August 2019 cut-off date was 1.7 months (range: 0.1-20.2) and 4.1 months (range: 0.0-23.5) in each group respectively.

  15. Overall Survival (OS) by Mutation Subgroups

    Overall survival is defined as the time from the date of randomization to the date of death. Participants who had not died were censored at the date they were last known to be alive on or before the cutoff date. Overall survival was analyzed using Kaplan-Meier methodology. Overall survival was analyzed in participants with the following molecular markers: * Isocitrate dehydrogenase 1 and 2 (IDH1/2) mutation * FMS (Feline McDonough Sarcoma)-like tyrosine kinase 3 (FLT3) mutation

    Time frame: From randomization until the analysis cut-off date of August 15, 2019; the median follow-up time was 17.7 months (range: 0.2 to 20.8) in the placebo arm and 17.5 months (range: 0.1 to 23.5) in the venetoclax arm.

  16. Percentage of Participants With Complete Remission or Complete Remission With Incomplete Blood Count Recovery (CR + CRi) by Mutation Subgroup

    Response was based on physical examination, bone marrow results and hematology values according to the revised guidelines by the IWG for AML: CR: No morphologic evidence of AML and ANC ≥ 10³/μL, platelets ≥ 10⁵/μL, RBC transfusion independence, and bone marrow with \< 5% blasts, absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease. CRi: All criteria as CR except for residual neutropenia \< 10³/μL or thrombocytopenia \< 10⁵/μL. If all criteria for CR are met except RBC transfusion independence, CRi criteria is met. Participants who had no IWG disease assessments were considered to be non-responders. Response was analyzed in participants with the following mutations: * Isocitrate dehydrogenase 1 and 2 (IDH1/2) mutation * FMS-like tyrosine kinase 3 (FLT3) mutation

    Time frame: Response was assessed at the end of Cycle 1 and every 3 cycles thereafter to the end of treatment. Median treatment duration at the 15 August 2019 cut-off date was 1.7 months (range: 0.1-20.2) and 4.1 months (range: 0.0-23.5) in each group respectively.

  17. Percentage of Participants With Complete Remission or Complete Remission With Partial Hematologic Recovery (CR + CRh) by Mutation Subgroup

    The percentage of participants who achieved a complete remission or complete remission with partial hematologic recovery assessed by the investigator for participants with the following mutations: * Isocitrate dehydrogenase 1 and 2 (IDH1/2) mutation * FMS-like tyrosine kinase 3 (FLT3) mutation CR is defined according to the modified IWG criteria for AML as no morphologic evidence of AML, ANC ≥ 10³/μL, platelets ≥ 10⁵/μL, RBC transfusion independence, bone marrow with \< 5% blasts, absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease. CRh is achieved when the following criteria are met: * Bone marrow with \< 5% blasts and * Peripheral blood neutrophil count \> 0.5 × 10³/μL and * Peripheral blood platelet count \> 0.5 × 10⁵/μL and * A 1 week platelet transfusion-free period prior to hematology lab collection. Participants with no disease assessments were considered non-responders

    Time frame: Response was assessed at the end of Cycle 1 and every 3 cycles thereafter to the end of treatment. Median treatment duration at the 15 August 2019 cut-off date was 1.7 months (range: 0.1-20.2) and 4.1 months (range: 0.0-23.5) in each group respectively.

07

Results

Posted Feb 28, 2020

Participant flow

Participants were enrolled at 76 sites globally.

Participant flow — Overall Study
MilestoneVenetoclax + Low Dose Cytarabine (LDAC)Placebo + Low Dose Cytarabine (LDAC)
Started14368
Completed00
Not completed14368
Withdrew: Withdrew consent64
Withdrew: Lost to follow-up20
Withdrew: Death12463
Withdrew: Other, not specified111

Outcome measures

PrimaryOverall Survival (OS)

Overall survival is defined as the time from the date of randomization to the date of death. Participants who had not died were censored at the date they were last known to be alive on or before the cutoff date. Overall survival was analyzed using Kaplan-Meier methodology.

Time frame:
From randomization until the primary analysis cut-off date of February 15 2019; the median follow-up time was 12.0 months (range: 0.2-17.0) in the placebo arm and 12.0 months (range: 0.1-17.6) in the venetoclax arm.
Reported as:
Median · months
Overall Survival (OS)
monthsVenetoclax + Low Dose Cytarabine (LDAC)Placebo + Low Dose Cytarabine (LDAC)
Overall Survival (OS)7.2 (5.6 to 10.1)4.1 (3.1 to 8.8)
Statistical analysis
  • Venetoclax + Low Dose Cytarabine (LDAC) vs Placebo + Low Dose Cytarabine (LDAC) · Log Rank · p = 0.114 · Hazard ratio (hr): 0.749 · 95% CI 0.524 to 1.071The hazard ratio was estimated using the Cox proportional hazards model, stratified by AML status (de novo, secondary) and age (18 - \< 75, ≥ 75).
  • Venetoclax + Low Dose Cytarabine (LDAC) vs Placebo + Low Dose Cytarabine (LDAC) · Log Rank · p = 0.103 · Hazard ratio (hr): 0.743 · 95% CI 0.521 to 1.061The hazard ratio was estimated using the Cox proportional hazards model.
SecondaryPercentage of Participants With Complete Remission or Complete Remission With Incomplete Blood Count Recovery (CR + CRi)

The composite complete remission rate is defined as the percentage of participants with complete remission (CR) or complete remission with incomplete blood count recovery (CRi) at any time during the study as assessed by the investigator. Response was based on physical examination, bone marrow results and hematology values according to the revised guidelines by the International Working Group (IWG) for AML: CR: No morphologic evidence of AML and absolute neutrophil count (ANC) ≥ 10³/μL (1,000/μL), platelets ≥ 10⁵/μL (100,000/μL), red blood cell (RBC) transfusion independence, and bone marrow with \< 5% blasts, absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease. CRi: All criteria as CR except for residual neutropenia \< 10³/μL or thrombocytopenia \< 10⁵/μL. If all criteria for CR are met except RBC transfusion independence, the CRi criteria are met. Participants who had no IWG disease assessments were considered to be non-responders.

Time frame:
Response was assessed at the end of Cycle 1 and every 3 cycles thereafter to the end of treatment. Median treatment duration at the 15 August 2019 cut-off date was 1.7 months (range: 0.1-20.2) and 4.1 months (range: 0.0-23.5) in each group respectively.
Reported as:
Number · percentage of participants
Percentage of Participants With Complete Remission or Complete Remission With Incomplete Blood Count Recovery (CR + CRi)
percentage of participantsVenetoclax + Low Dose Cytarabine (LDAC)Placebo + Low Dose Cytarabine (LDAC)
Percentage of Participants With Complete Remission or Complete Remission With Incomplete Blood Count Recovery (CR + CRi)48.3 (39.8 to 56.8)13.2 (6.2 to 23.6)
Statistical analysis
  • Venetoclax + Low Dose Cytarabine (LDAC) vs Placebo + Low Dose Cytarabine (LDAC) · Cochran-Mantel-Haenszel · p = <0.001Cochran-Mantel-Haenszel test stratified by age (18 - \< 75, ≥ 75) and AML status (de novo, secondary).
  • Venetoclax + Low Dose Cytarabine (LDAC) vs Placebo + Low Dose Cytarabine (LDAC) · Fisher Exact · p = <0.001
SecondaryPercentage of Participants With Complete Remission or Complete Remission With Partial Hematologic Recovery (CR + CRh)

The percentage of participants who achieved a complete remission (CR) or complete remission with partial hematologic recovery (CRh) at any time point during the study assessed by the investigator. CR is defined according to the revised guidelines by the IWG for AML as no morphologic evidence of AML, ANC count ≥ 10³/μL, platelets ≥ 10⁵/μL, RBC transfusion independence, and bone marrow with \< 5% blasts, absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease. CRh is a derived response based on bone marrow blast and hematology lab values, achieved when the following criteria are met: * Bone marrow with \< 5% blasts and * Peripheral blood neutrophil count of \> 0.5 × 10³/μL and * Peripheral blood platelet count of \> 0.5 × 10⁵/μL and * A 1 week platelet transfusion-free period prior to the hematology lab collection. Participants with no disease assessments were considered to be non-responders.

Time frame:
Response was assessed at the end of Cycle 1 and every 3 cycles thereafter to the end of treatment. Median treatment duration at the 15 August 2019 cut-off date was 1.7 months (range: 0.1-20.2) and 4.1 months (range: 0.0-23.5) in each group respectively.
Reported as:
Number · percentage of participants
Percentage of Participants With Complete Remission or Complete Remission With Partial Hematologic Recovery (CR + CRh)
percentage of participantsVenetoclax + Low Dose Cytarabine (LDAC)Placebo + Low Dose Cytarabine (LDAC)
Percentage of Participants With Complete Remission or Complete Remission With Partial Hematologic Recovery (CR + CRh)48.3 (39.8 to 56.8)14.7 (7.3 to 25.4)
Statistical analysis
  • Venetoclax + Low Dose Cytarabine (LDAC) vs Placebo + Low Dose Cytarabine (LDAC) · Cochran-Mantel-Haenszel · p = <0.001Cochran-Mantel-Haenszel test stratified by age (18 - \< 75, ≥ 75) and AML status (de novo, secondary).
  • Venetoclax + Low Dose Cytarabine (LDAC) vs Placebo + Low Dose Cytarabine (LDAC) · Fisher Exact · p = <0.001
SecondaryPercentage of Participants With Complete Remission or Complete Remission With Incomplete Blood Count Recovery (CR + CRi) by Initiation of Cycle 2

The composite complete remission rate is defined as the percentage of participants with complete remission (CR) or complete remission with incomplete blood count recovery (CRi) before initiation of Cycle 2, assessed by the investigator. Response was based on physical examination, bone marrow results and hematology values according to the revised guidelines by the IWG for AML: CR: No morphologic evidence of AML and absolute neutrophil count ≥ 10³/μL, platelets ≥ 10⁵/μL, red cell transfusion independence, and bone marrow with \< 5% blasts, absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease. CRi: All criteria as CR except for residual neutropenia \< 10³/μL or thrombocytopenia \< 10⁵/μL. If all criteria for CR are met except for RBC transfusion independence, CRi criteria are met. Participants who had no IWG disease assessments were considered to be non-responders.

Time frame:
Cycle 1, 28 days
Reported as:
Number · percentage of participants
Percentage of Participants With Complete Remission or Complete Remission With Incomplete Blood Count Recovery (CR + CRi) by Initiation of Cycle 2
percentage of participantsVenetoclax + Low Dose Cytarabine (LDAC)Placebo + Low Dose Cytarabine (LDAC)
Percentage of Participants With Complete Remission or Complete Remission With Incomplete Blood Count Recovery (CR + CRi) by Initiation of Cycle 234.3 (26.5 to 42.7)2.9 (0.4 to 10.2)
Statistical analysis
  • Venetoclax + Low Dose Cytarabine (LDAC) vs Placebo + Low Dose Cytarabine (LDAC) · Cochran-Mantel-Haenszel · p = <0.001Cochran-Mantel-Haenszel test stratified by age (18 - \< 75, ≥ 75) and AML status (de novo, secondary).
  • Venetoclax + Low Dose Cytarabine (LDAC) vs Placebo + Low Dose Cytarabine (LDAC) · Fisher Exact · p = <0.001
SecondaryPercentage of Participants With Complete Remission and Complete Remission With Partial Hematologic Recovery (CR + CRh) by Initiation of Cycle 2

The percentage of participants who achieved a complete remission (CR) or complete remission with partial hematologic recovery (CRh) before initiation of Cycle 2 assessed by the investigator. CR is defined according to the revised guidelines by the IWG for AML as no morphologic evidence of AML, ANC count ≥ 10³/μL, platelets ≥ 10⁵/μL, RBC transfusion independence, and bone marrow with \< 5% blasts, absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease. CRh is a derived response based on bone marrow blast and hematology lab values, achieved when when the following criteria are met: * Bone marrow with \< 5% blasts and * Peripheral blood neutrophil count of \> 0.5 × 10³/μL and * Peripheral blood platelet count of \> 0.5 × 10⁵/μL and * A 1-week platelet transfusion-free period prior to the hematology lab collection. Participants with no disease assessments were considered to be non-responders.

Time frame:
Cycle 1, 28 days
Reported as:
Number · percentage of participants
Percentage of Participants With Complete Remission and Complete Remission With Partial Hematologic Recovery (CR + CRh) by Initiation of Cycle 2
percentage of participantsVenetoclax + Low Dose Cytarabine (LDAC)Placebo + Low Dose Cytarabine (LDAC)
Percentage of Participants With Complete Remission and Complete Remission With Partial Hematologic Recovery (CR + CRh) by Initiation of Cycle 230.8 (23.3 to 39.0)4.4 (0.9 to 12.4)
Statistical analysis
  • Venetoclax + Low Dose Cytarabine (LDAC) vs Placebo + Low Dose Cytarabine (LDAC) · Cochran-Mantel-Haenszel · p = <0.001Cochran-Mantel-Haenszel test stratified by age (18 - \< 75, ≥ 75) and AML status (de novo, secondary).
  • Venetoclax + Low Dose Cytarabine (LDAC) vs Placebo + Low Dose Cytarabine (LDAC) · Fisher Exact · p = <0.001
SecondaryPercentage of Participants With Complete Remission

The complete remission rate is defined as the percentage of participants with complete remission (CR) at any time during the study as assessed by the investigator. Response was based on physical examination, bone marrow results and hematology values according to the revised guidelines by the International Working Group (IWG) for AML. CR is defined as no morphologic evidence of AML and absolute neutrophil count ≥ 10³/μL, platelets ≥ 10⁵/μL, red blood cell transfusion independence, and bone marrow with \< 5% blasts, absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease. Participants who had no IWG disease assessments were considered to be non-responders.

Time frame:
Response was assessed at the end of Cycle 1 and every 3 cycles thereafter to the end of treatment. Median treatment duration at the 15 August 2019 cut-off date was 1.7 months (range: 0.1-20.2) and 4.1 months (range: 0.0-23.5) in each group respectively.
Reported as:
Number · percentage of participants
Percentage of Participants With Complete Remission
percentage of participantsVenetoclax + Low Dose Cytarabine (LDAC)Placebo + Low Dose Cytarabine (LDAC)
Percentage of Participants With Complete Remission28.0 (20.8 to 36.1)7.4 (2.4 to 16.3)
Statistical analysis
  • Venetoclax + Low Dose Cytarabine (LDAC) vs Placebo + Low Dose Cytarabine (LDAC) · Cochran-Mantel-Haenszel · p = <0.001Cochran-Mantel-Haenszel test stratified by age (18 - \< 75, ≥ 75) and AML status (de novo, secondary).
  • Venetoclax + Low Dose Cytarabine (LDAC) vs Placebo + Low Dose Cytarabine (LDAC) · Fisher Exact · p = <0.001
SecondaryChange From Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue Short Form (SF) 7a

PROMIS Fatigue SF 7a is a seven-item questionnaire that assesses the impact and experience of fatigue over the past 7 days. All questions employ the following five response options: 1 = Never, 2 = Rarely, 3 = Sometimes, 4 = Often, and 5 = Always. The PROMIS Fatigue 7a score is calculated as a T-score, which is a standardized score with a mean of 50 (based on the average for the United States general population) and a standard deviation (SD) of 10. Higher scores indicate higher levels of fatigue. A decrease in score (negative change from Baseline) indicates improvement in fatigue; the minimum important difference used in this study was 3 points.

Time frame:
Baseline and Day 1 of Cycles 3, 5, 7, 9, and 11
Reported as:
Least squares mean · score on a scale
Change From Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue Short Form (SF) 7a
score on a scaleVenetoclax + Low Dose Cytarabine (LDAC)Placebo + Low Dose Cytarabine (LDAC)
Cycle 3 Day 1-3.410 ± 1.0621.110 ± 1.826
Cycle 5 Day 1-5.489 ± 1.219-0.538 ± 2.187
Cycle 7 Day 1-4.376 ± 1.242-3.855 ± 2.191
Cycle 9 Day 1-5.562 ± 1.431-3.326 ± 2.582
Cycle 11 Day 1-4.944 ± 1.653-1.269 ± 3.057
Statistical analysis
  • Venetoclax + Low Dose Cytarabine (LDAC) vs Placebo + Low Dose Cytarabine (LDAC) · Ls mean difference: -4.520 · 95% CI -8.54 to -0.50A linear mixed-effects regression model with a covariance structure including baseline score, stratification factors (age and AML status) treatment arm, visit, and treatment arm by visit interaction.
  • Venetoclax + Low Dose Cytarabine (LDAC) vs Placebo + Low Dose Cytarabine (LDAC) · Ls mean difference: -4.951 · 95% CI -9.75 to -0.15A linear mixed-effects regression model with a covariance structure including baseline score, stratification factors (age and AML status) treatment arm, visit, and treatment arm by visit interaction.
  • Venetoclax + Low Dose Cytarabine (LDAC) vs Placebo + Low Dose Cytarabine (LDAC) · Ls mean difference: -0.522 · 95% CI -5.35 to 4.31A linear mixed-effects regression model with a covariance structure including baseline score, stratification factors (age and AML status) treatment arm, visit, and treatment arm by visit interaction.
  • Venetoclax + Low Dose Cytarabine (LDAC) vs Placebo + Low Dose Cytarabine (LDAC) · Ls mean difference: -2.236 · 95% CI -7.94 to 3.47A linear mixed-effects regression model with a covariance structure including baseline score, stratification factors (age and AML status) treatment arm, visit, and treatment arm by visit interaction.
  • Venetoclax + Low Dose Cytarabine (LDAC) vs Placebo + Low Dose Cytarabine (LDAC) · Ls mean difference: -3.675 · 95% CI -10.44 to 3.09A linear mixed-effects regression model with a covariance structure including baseline score, stratification factors (age and AML status) treatment arm, visit, and treatment arm by visit interaction.
  • Venetoclax + Low Dose Cytarabine (LDAC) vs Placebo + Low Dose Cytarabine (LDAC) · Linear Mixed Effects Regression Model · p = 0.098Model included AML status (de novo vs. secondary), age (18-\< 75 vs. ≥ 75), treatment arm, time, and treatment arm by time interaction as fixed factors
SecondaryChange From Baseline in Global Health Status/Quality of Life

The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core (EORTC QLQ-C30) consists of a Global Health Status/Quality of Life (GHS/QoL) scale, a Financial Difficulties scale, 5 functional scales (Cognitive, Social, Physical, Emotional, and Role Functioning), and 8 symptom scales/items (Fatigue, Insomnia, Appetite Loss, Pain, Constipation, Diarrhea, Dyspnea, and Nausea and Vomiting). The GHS/QoL scale includes 2 questions in which participants were asked to rate their overall health and overall quality of life during the past week on a scale from 1 (very poor) to 7 (excellent). The 2 scores were averaged and transformed to a scale from 0 to 100, where a high score represents a high QoL. A positive change from baseline indicates better quality of life.

Time frame:
Baseline and Day 1 of Cycles 3, 5, 7, 9, and 11
Reported as:
Least squares mean · score on a scale
Change From Baseline in Global Health Status/Quality of Life
score on a scaleVenetoclax + Low Dose Cytarabine (LDAC)Placebo + Low Dose Cytarabine (LDAC)
Cycle 3 Day 15.655 ± 2.4272.838 ± 4.192
Cycle 5 Day 114.841 ± 2.7615.724 ± 4.982
Cycle 7 Day 19.783 ± 2.9295.913 ± 5.235
Cycle 9 Day 115.291 ± 3.4478.837 ± 6.356
Cycle 11 Day 111.753 ± 4.18811.366 ± 7.926
Statistical analysis
  • Venetoclax + Low Dose Cytarabine (LDAC) vs Placebo + Low Dose Cytarabine (LDAC) · Ls mean difference: 2.817 · 95% CI -6.46 to 12.09A linear mixed-effects regression model with a covariance structure including baseline score, stratification factors (age and AML status) treatment arm, visit, and treatment arm by visit interaction.
  • Venetoclax + Low Dose Cytarabine (LDAC) vs Placebo + Low Dose Cytarabine (LDAC) · Ls mean difference: 9.117 · 95% CI -1.86 to 20.09A linear mixed-effects regression model with a covariance structure including baseline score, stratification factors (age and AML status) treatment arm, visit, and treatment arm by visit interaction.
  • Venetoclax + Low Dose Cytarabine (LDAC) vs Placebo + Low Dose Cytarabine (LDAC) · Ls mean difference: 3.869 · 95% CI -7.69 to 15.43A linear mixed-effects regression model with a covariance structure including baseline score, stratification factors (age and AML status) treatment arm, visit, and treatment arm by visit interaction.
  • Venetoclax + Low Dose Cytarabine (LDAC) vs Placebo + Low Dose Cytarabine (LDAC) · Ls mean difference: 6.454 · 95% CI -7.58 to 20.49A linear mixed-effects regression model with a covariance structure including baseline score, stratification factors (age and AML status) treatment arm, visit, and treatment arm by visit interaction.
  • Venetoclax + Low Dose Cytarabine (LDAC) vs Placebo + Low Dose Cytarabine (LDAC) · Ls mean difference: 0.388 · 95% CI -17.15 to 17.92A linear mixed-effects regression model with a covariance structure including baseline score, stratification factors (age and AML status) treatment arm, visit, and treatment arm by visit interaction.
  • Venetoclax + Low Dose Cytarabine (LDAC) vs Placebo + Low Dose Cytarabine (LDAC) · Linear Mixed Effects Regression Model · p = 0.296 (P-Value for treatment effect)Model included AML status (de novo vs. secondary), age (18-\< 75 vs. ≥ 75), treatment arm, time, and treatment arm by time interaction as fixed factors
SecondaryEvent-free Survival (EFS)

Event-free survival is defined as the time from randomization to the date of progressive disease (PD), confirmed morphologic relapse from CR or CRi, treatment failure (failure to achieve CR, CRi or morphologic leukemia free state (MLFS) after at least 6 cycles of study treatment), or death from any cause, assessed by the investigator according to the modified IWG criteria. PD: * \> 50% increase in marrow blasts (minimum 15% increase required if blasts \< 30% at baseline); or persistent marrow blast \> 70% for ≥ 3 months; without at least a 100% improvement in ANC to an absolute level \> 0.5 × 10⁹/L, and/or platelets to \> 50 × 10⁹/L non-transfused; or * 50% increase in peripheral blasts to \> 25 × 10⁹/L; or * New extramedullary disease Participants with no events prior to the cut-off date were censored at their last assessment date; participants with no events prior to post-treatment therapy initiated before the cut-off date were censored on the start date of post-treatment therapy.

Time frame:
From randomization until the analysis cut-off date of August 15, 2019; the median follow-up time was 17.7 months (range: 0.2 to 20.8) in the placebo arm and 17.5 months (range: 0.1 to 23.5) in the venetoclax arm.
Reported as:
Median · months
Event-free Survival (EFS)
monthsVenetoclax + Low Dose Cytarabine (LDAC)Placebo + Low Dose Cytarabine (LDAC)
Event-free Survival (EFS)4.9 (3.7 to 6.4)2.1 (1.5 to 3.2)
Statistical analysis
  • Venetoclax + Low Dose Cytarabine (LDAC) vs Placebo + Low Dose Cytarabine (LDAC) · Log Rank · p = 0.002 · Hazard ratio (hr): 0.610 · 95% CI 0.442 to 0.841The hazard ratio was estimated using the Cox proportional hazards model, stratified by AML status (de novo, secondary) and age (18 - \< 75, ≥ 75).
  • Venetoclax + Low Dose Cytarabine (LDAC) vs Placebo + Low Dose Cytarabine (LDAC) · Log Rank · p = 0.005 · Hazard ratio (hr): 0.638 · 95% CI 0.464 to 0.876The hazard ratio was estimated using the Cox proportional hazards model.
SecondaryPercentage of Participants With Post Baseline Red Blood Cell (RBC) Transfusion Independence

The post baseline red blood cell (RBC) transfusion independence rate was calculated as the percentage of participants who achieved RBC transfusion independence post baseline. RBC transfusion independence is defined as a period of at least 56 consecutive days with no RBC transfusion after the first dose of study drug and on or before the last dose of study drug plus 30 days, or disease progression, or confirmed morphological relapse, or death, or the data cut-off date, whichever occurred earlier.

Time frame:
From first dose of study drug until 30 days after last dose up to the data cut-off date of 15 August 2019; Median time on treatment was 1.7 months (range: 0.1-20.2) in the placebo arm and 4.1 months (range: 0.0-23.5) in the venetoclax arm.
Reported as:
Number · percentage of participants
Percentage of Participants With Post Baseline Red Blood Cell (RBC) Transfusion Independence
percentage of participantsVenetoclax + Low Dose Cytarabine (LDAC)Placebo + Low Dose Cytarabine (LDAC)
Percentage of Participants With Post Baseline Red Blood Cell (RBC) Transfusion Independence43.4 (35.1 to 51.9)19.1 (10.6 to 30.5)
Statistical analysis
  • Venetoclax + Low Dose Cytarabine (LDAC) vs Placebo + Low Dose Cytarabine (LDAC) · Cochran-Mantel-Haenszel · p = <0.001 · Treatment difference: 24.2 · 95% CI 11.9 to 36.6Treatment difference = Venetoclax - Placebo
  • Venetoclax + Low Dose Cytarabine (LDAC) vs Placebo + Low Dose Cytarabine (LDAC) · Fisher Exact · p = <0.001
SecondaryPercentage of Participants With Post Baseline Platelet Transfusion Independence

The post baseline platelet transfusion independence rate was calculated as the percentage of participants who achieved platelet transfusion independence post Baseline. Platelet transfusion independence is defined as a period of at least 56 consecutive days with no platelet transfusion after the first dose of study drug and on or before the last dose of study drug plus 30 days, or disease progression, or confirmed morphological relapse, or death, or the data cut--off date, whichever occurred earlier.

Time frame:
From first dose of study drug until 30 days after last dose up to the data cut-off date of 15 August 2019; Median time on treatment was 1.7 months (range: 0.1-20.2) in the placebo arm and 4.1 months (range: 0.0-23.5) in the venetoclax arm.
Reported as:
Number · percentage of participants
Percentage of Participants With Post Baseline Platelet Transfusion Independence
percentage of participantsVenetoclax + Low Dose Cytarabine (LDAC)Placebo + Low Dose Cytarabine (LDAC)
Percentage of Participants With Post Baseline Platelet Transfusion Independence49.0 (40.5 to 57.4)32.4 (21.5 to 44.8)
Statistical analysis
  • Venetoclax + Low Dose Cytarabine (LDAC) vs Placebo + Low Dose Cytarabine (LDAC) · Cochran-Mantel-Haenszel · p = 0.024 · Treatment difference: 16.6 · 95% CI 2.8 to 30.4Treatment difference = Venetoclax - Placebo
  • Venetoclax + Low Dose Cytarabine (LDAC) vs Placebo + Low Dose Cytarabine (LDAC) · Fisher Exact · p = 0.026
SecondaryPercentage of Participants With RBC Transfusion Independence Among Those Who Were Transfusion Dependent at Baseline

The rate of conversion was calculated as the percentage of participants who were post-baseline RBC transfusion independent among participants who had an RBC transfusion within 8 weeks prior to the first dose of study drug (i.e. were transfusion dependent at Baseline). RBC transfusion independence is defined as a period of at least 56 days with no RBC transfusion after the first dose of study drug and on or before the last dose of study drug plus 30 days, or disease progression, or confirmed morphological relapse, or death, or the data cut-off date, whichever occurred earlier.

Time frame:
From first dose of study drug until 30 days after last dose up to the data cut-off date of 15 August 2019; Median time on treatment was 1.7 months (range: 0.1-20.2) in the placebo arm and 4.1 months (range: 0.0-23.5) in the venetoclax arm.
Reported as:
Number · percentage of participants
Percentage of Participants With RBC Transfusion Independence Among Those Who Were Transfusion Dependent at Baseline
percentage of participantsVenetoclax + Low Dose Cytarabine (LDAC)Placebo + Low Dose Cytarabine (LDAC)
Percentage of Participants With RBC Transfusion Independence Among Those Who Were Transfusion Dependent at Baseline40.4 (30.9 to 50.5)16.7 (7.9 to 29.3)
Statistical analysis
  • Venetoclax + Low Dose Cytarabine (LDAC) vs Placebo + Low Dose Cytarabine (LDAC) · Treatment difference: 23.7 · 95% CI 10.0 to 37.4
SecondaryPercentage of Participants With Platelet Transfusion Independence Among Those Who Were Transfusion Dependent at Baseline

The rate of conversion was calculated as the percentage of participants who were post-baseline platelet transfusion independent among participants who had a platelet transfusion within 8 weeks prior to the first dose of study drug (i.e. were transfusion dependent at Baseline). Platelet transfusion independence is defined as a period of at least 56 days with no platelet transfusion after the first dose of study drug and on or before the last dose of study drug plus 30 days, or disease progression, or confirmed morphological relapse, or death, or the data cut-off date, whichever occurred earlier.

Time frame:
From first dose of study drug until 30 days after last dose up to the data cut-off date of 15 August 2019; Median time on treatment was 1.7 months (range: 0.1-20.2) in the placebo arm and 4.1 months (range: 0.0-23.5) in the venetoclax arm.
Reported as:
Number · percentage of participants
Percentage of Participants With Platelet Transfusion Independence Among Those Who Were Transfusion Dependent at Baseline
percentage of participantsVenetoclax + Low Dose Cytarabine (LDAC)Placebo + Low Dose Cytarabine (LDAC)
Percentage of Participants With Platelet Transfusion Independence Among Those Who Were Transfusion Dependent at Baseline28.8 (17.1 to 43.1)12.5 (2.7 to 32.4)
Statistical analysis
  • Venetoclax + Low Dose Cytarabine (LDAC) vs Placebo + Low Dose Cytarabine (LDAC) · Slope: 16.3 · 95% CI -1.7 to 34.4
SecondaryPercentage of Participants With Complete Remission or Complete Remission With Incomplete Blood Count Recovery (CR + CRi) and Minimal Residual Disease (MRD) Response

The percentage of participants with complete remission or complete remission with incomplete blood count recovery AND minimal residual disease (MRD) as assessed by the investigator. Response was based on the modified IWG response criteria for AML: CR: No morphologic evidence of AML and ANC ≥ 10³/μL, platelets ≥ 10⁵/μL, red blood cell (RBC) transfusion independence, and bone marrow with \< 5% blasts, absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease. CRi: All criteria as CR except for residual neutropenia \< 10³/μL or thrombocytopenia \< 10⁵/μL. If all criteria for CR are met except RBC transfusion independence, CRi criteria are met. MRD response (at lowest-point MRD value) was defined as having less than 10-³ residual blasts per leukocyte measured in the bone marrow, per European LeukemiaNet (ELN) recommendations. Participants who had no disease or MRD assessments were considered to be non-responders.

Time frame:
Response was assessed at the end of Cycle 1 and every 3 cycles thereafter to the end of treatment. Median treatment duration at the 15 August 2019 cut-off date was 1.7 months (range: 0.1-20.2) and 4.1 months (range: 0.0-23.5) in each group respectively.
Reported as:
Number · percentage of participants
Percentage of Participants With Complete Remission or Complete Remission With Incomplete Blood Count Recovery (CR + CRi) and Minimal Residual Disease (MRD) Response
percentage of participantsVenetoclax + Low Dose Cytarabine (LDAC)Placebo + Low Dose Cytarabine (LDAC)
Percentage of Participants With Complete Remission or Complete Remission With Incomplete Blood Count Recovery (CR + CRi) and Minimal Residual Disease (MRD) Response6.3 (2.9 to 11.6)1.5 (0.0 to 7.9)
Statistical analysis
  • Venetoclax + Low Dose Cytarabine (LDAC) vs Placebo + Low Dose Cytarabine (LDAC) · Cochran-Mantel-Haenszel · p = 0.118Cochran-Mantel-Haenszel test stratified by age (18 - \< 75, ≥ 75) and AML status (de novo, secondary).
  • Venetoclax + Low Dose Cytarabine (LDAC) vs Placebo + Low Dose Cytarabine (LDAC) · Fisher Exact · p = 0.173
SecondaryPercentage of Participants With Complete Remission or Complete Remission With Partial Hematologic Recovery (CR + CRh) and Minimal Residual Disease (MRD) Response

The percentage of participants with complete remission or complete remission with partial hematologic recovery (CRh) AND MRD response as assessed by the investigator. CR is defined according to the modified IWG response criteria for AML as no morphologic evidence of AML, ANC ≥ 10³/μL, platelets ≥ 10⁵/μL, RBC transfusion independence, and bone marrow with \< 5% blasts, absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease. CRh is achieved when the following criteria are met: * Bone marrow with \< 5% blasts and * Peripheral blood neutrophil count of \> 0.5 × 10³/μL and * Peripheral blood platelet count of \> 0.5 × 10⁵/μL and * A 1 week platelet transfusion-free period prior to the hematology lab collection. MRD response (at lowest-point MRD value) was defined as less than 10-³ residual blasts per leukocyte measured in the bone marrow, per ELN recommendations. Participants who had no disease or MRD assessments were considered to be non-responders.

Time frame:
Response was assessed at the end of Cycle 1 and every 3 cycles thereafter to the end of treatment. Median treatment duration at the 15 August 2019 cut-off date was 1.7 months (range: 0.1-20.2) and 4.1 months (range: 0.0-23.5) in each group respectively.
Reported as:
Number · percentage of participants
Percentage of Participants With Complete Remission or Complete Remission With Partial Hematologic Recovery (CR + CRh) and Minimal Residual Disease (MRD) Response
percentage of participantsVenetoclax + Low Dose Cytarabine (LDAC)Placebo + Low Dose Cytarabine (LDAC)
Percentage of Participants With Complete Remission or Complete Remission With Partial Hematologic Recovery (CR + CRh) and Minimal Residual Disease (MRD) Response6.3 (2.9 to 11.6)1.5 (0.0 to 7.9)
Statistical analysis
  • Venetoclax + Low Dose Cytarabine (LDAC) vs Placebo + Low Dose Cytarabine (LDAC) · Cochran-Mantel-Haenszel · p = 0.118Cochran-Mantel-Haenszel test stratified by age (18 - \< 75, ≥ 75) and AML status (de novo, secondary).
  • Venetoclax + Low Dose Cytarabine (LDAC) vs Placebo + Low Dose Cytarabine (LDAC) · Fisher Exact · p = 0.173
SecondaryOverall Survival (OS) by Mutation Subgroups

Overall survival is defined as the time from the date of randomization to the date of death. Participants who had not died were censored at the date they were last known to be alive on or before the cutoff date. Overall survival was analyzed using Kaplan-Meier methodology. Overall survival was analyzed in participants with the following molecular markers: * Isocitrate dehydrogenase 1 and 2 (IDH1/2) mutation * FMS (Feline McDonough Sarcoma)-like tyrosine kinase 3 (FLT3) mutation

Time frame:
From randomization until the analysis cut-off date of August 15, 2019; the median follow-up time was 17.7 months (range: 0.2 to 20.8) in the placebo arm and 17.5 months (range: 0.1 to 23.5) in the venetoclax arm.
Reported as:
Median · months
Overall Survival (OS) by Mutation Subgroups
monthsVenetoclax + Low Dose Cytarabine (LDAC)Placebo + Low Dose Cytarabine (LDAC)
IDH1/2 mutation11.2 (4.2 to 20.8)9.0 (2.2 to NA)
FLT3 mutation5.9 (1.6 to 20.8)9.8 (0.9 to NA)
Statistical analysis
  • Venetoclax + Low Dose Cytarabine (LDAC) vs Placebo + Low Dose Cytarabine (LDAC) · Log Rank · p = 0.442 · Hazard ratio (hr): 0.709 · 95% CI 0.298 to 1.691The hazard ratio was estimated using the Cox proportional hazards model.
  • Venetoclax + Low Dose Cytarabine (LDAC) vs Placebo + Low Dose Cytarabine (LDAC) · Log Rank · p = 0.916 · Hazard ratio (hr): 0.954 · 95% CI 0.358 to 2.545The hazard ratio was estimated using the Cox proportional hazards model.
SecondaryPercentage of Participants With Complete Remission or Complete Remission With Incomplete Blood Count Recovery (CR + CRi) by Mutation Subgroup

Response was based on physical examination, bone marrow results and hematology values according to the revised guidelines by the IWG for AML: CR: No morphologic evidence of AML and ANC ≥ 10³/μL, platelets ≥ 10⁵/μL, RBC transfusion independence, and bone marrow with \< 5% blasts, absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease. CRi: All criteria as CR except for residual neutropenia \< 10³/μL or thrombocytopenia \< 10⁵/μL. If all criteria for CR are met except RBC transfusion independence, CRi criteria is met. Participants who had no IWG disease assessments were considered to be non-responders. Response was analyzed in participants with the following mutations: * Isocitrate dehydrogenase 1 and 2 (IDH1/2) mutation * FMS-like tyrosine kinase 3 (FLT3) mutation

Time frame:
Response was assessed at the end of Cycle 1 and every 3 cycles thereafter to the end of treatment. Median treatment duration at the 15 August 2019 cut-off date was 1.7 months (range: 0.1-20.2) and 4.1 months (range: 0.0-23.5) in each group respectively.
Reported as:
Number · percentage of participants
Percentage of Participants With Complete Remission or Complete Remission With Incomplete Blood Count Recovery (CR + CRi) by Mutation Subgroup
percentage of participantsVenetoclax + Low Dose Cytarabine (LDAC)Placebo + Low Dose Cytarabine (LDAC)
IDH1/2 mutation57.1 (34.0 to 78.2)33.3 (9.9 to 65.1)
FLT3 mutation45.0 (23.1 to 68.5)44.4 (13.7 to 78.8)
Statistical analysis
  • Venetoclax + Low Dose Cytarabine (LDAC) vs Placebo + Low Dose Cytarabine (LDAC) · Fisher Exact · p = 0.282
  • Venetoclax + Low Dose Cytarabine (LDAC) vs Placebo + Low Dose Cytarabine (LDAC) · Fisher Exact · p = 1.000
SecondaryPercentage of Participants With Complete Remission or Complete Remission With Partial Hematologic Recovery (CR + CRh) by Mutation Subgroup

The percentage of participants who achieved a complete remission or complete remission with partial hematologic recovery assessed by the investigator for participants with the following mutations: * Isocitrate dehydrogenase 1 and 2 (IDH1/2) mutation * FMS-like tyrosine kinase 3 (FLT3) mutation CR is defined according to the modified IWG criteria for AML as no morphologic evidence of AML, ANC ≥ 10³/μL, platelets ≥ 10⁵/μL, RBC transfusion independence, bone marrow with \< 5% blasts, absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease. CRh is achieved when the following criteria are met: * Bone marrow with \< 5% blasts and * Peripheral blood neutrophil count \> 0.5 × 10³/μL and * Peripheral blood platelet count \> 0.5 × 10⁵/μL and * A 1 week platelet transfusion-free period prior to hematology lab collection. Participants with no disease assessments were considered non-responders

Time frame:
Response was assessed at the end of Cycle 1 and every 3 cycles thereafter to the end of treatment. Median treatment duration at the 15 August 2019 cut-off date was 1.7 months (range: 0.1-20.2) and 4.1 months (range: 0.0-23.5) in each group respectively.
Reported as:
Number · percentage of participants
Percentage of Participants With Complete Remission or Complete Remission With Partial Hematologic Recovery (CR + CRh) by Mutation Subgroup
percentage of participantsVenetoclax + Low Dose Cytarabine (LDAC)Placebo + Low Dose Cytarabine (LDAC)
IDH1/2 mutation57.1 (34.0 to 78.2)33.3 (9.9 to 65.1)
FLT3 mutation50.0 (27.2 to 72.8)44.4 (13.7 to 78.8)
Statistical analysis
  • Venetoclax + Low Dose Cytarabine (LDAC) vs Placebo + Low Dose Cytarabine (LDAC) · Fisher Exact · p = 0.282
  • Venetoclax + Low Dose Cytarabine (LDAC) vs Placebo + Low Dose Cytarabine (LDAC) · Fisher Exact · p = 1.000
Post-hocOverall Survival After an Additional 6-Months Follow-up

Overall survival is defined as the time from the date of randomization to the date of death. Participants who had not died were censored at the date they were last known to be alive on or before the cutoff date. Overall survival was analyzed using Kaplan-Meier methodology.

Time frame:
From randomization until the 6-month follow-up analysis cut-off date of August 15, 2019; the median follow-up time was 17.7 months (range: 0.2-20.8) in the placebo arm and 17.5 months (range: 0.1-23.5) in the venetoclax arm.
Reported as:
Median · months
Overall Survival After an Additional 6-Months Follow-up
monthsVenetoclax + Low Dose Cytarabine (LDAC)Placebo + Low Dose Cytarabine (LDAC)
Overall Survival After an Additional 6-Months Follow-up8.4 (5.9 to 10.1)4.1 (3.1 to 8.1)
Statistical analysis
  • Venetoclax + Low Dose Cytarabine (LDAC) vs Placebo + Low Dose Cytarabine (LDAC) · Log Rank · p = 0.040 · Hazard ratio (hr): 0.704 · 95% CI 0.503 to 0.985The hazard ratio was estimated using the Cox proportional hazards model, stratified by AML status (de novo, secondary) and age (18 - \< 75, ≥ 75).
  • Venetoclax + Low Dose Cytarabine (LDAC) vs Placebo + Low Dose Cytarabine (LDAC) · Log Rank · p = 0.049 · Hazard ratio (hr): 0.717 · 95% CI 0.514 to 1.000The hazard ratio was estimated using the Cox proportional hazards model.

Adverse events

Collected over All protocol-related serious adverse events and nonserious adverse events were collected from informed consent until study drug start, up to 21 days. All adverse events were collected from the time of study drug administration until 30 days after the last dose, up to 90.0 months for VEN + LDAC and 33.3 months for PBO + LDAC. Median time on follow-up: VEN + LDAC (8.4 months); PBO + LDAC (4.1 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Venetoclax + Low Dose Cytarabine (LDAC)126/143 (88.1%)103/143 (72%)131/143 (91.6%)
Placebo + Low Dose Cytarabine (LDAC)64/68 (94.1%)43/68 (63.2%)62/68 (91.2%)
Most frequent serious events
Showing 10 of 141
Most frequent serious events
EventVenetoclax + Low Dose Cytarabine (LDAC)Placebo + Low Dose Cytarabine (LDAC)
PNEUMONIAINFECTIONS AND INFESTATIONS29/1439/68
FEBRILE NEUTROPENIABLOOD AND LYMPHATIC SYSTEM DISORDERS25/14312/68
PYREXIAGENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS3/1435/68
SEPSISINFECTIONS AND INFESTATIONS9/1433/68
SEPTIC SHOCKINFECTIONS AND INFESTATIONS5/1434/68
THROMBOCYTOPENIABLOOD AND LYMPHATIC SYSTEM DISORDERS8/1432/68
CARDIAC FAILURECARDIAC DISORDERS2/1433/68
ANAEMIABLOOD AND LYMPHATIC SYSTEM DISORDERS5/1430/68
CELLULITISINFECTIONS AND INFESTATIONS5/1432/68
LEUKOCYTOSISBLOOD AND LYMPHATIC SYSTEM DISORDERS1/1432/68
Most frequent other events
Showing 10 of 56
Most frequent other events
EventVenetoclax + Low Dose Cytarabine (LDAC)Placebo + Low Dose Cytarabine (LDAC)
NAUSEAGASTROINTESTINAL DISORDERS65/14322/68
NEUTROPENIABLOOD AND LYMPHATIC SYSTEM DISORDERS64/14312/68
THROMBOCYTOPENIABLOOD AND LYMPHATIC SYSTEM DISORDERS59/14325/68
DIARRHOEAGASTROINTESTINAL DISORDERS47/14313/68
HYPOKALAEMIAMETABOLISM AND NUTRITION DISORDERS47/14317/68
CONSTIPATIONGASTROINTESTINAL DISORDERS31/14322/68
VOMITINGGASTROINTESTINAL DISORDERS42/14310/68
ANAEMIABLOOD AND LYMPHATIC SYSTEM DISORDERS38/14315/68
DECREASED APPETITEMETABOLISM AND NUTRITION DISORDERS31/14313/68
OEDEMA PERIPHERALGENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS21/14314/68

Baseline characteristics

Age, Continuous
Age, Continuous(years)Venetoclax + Low Dose Cytarabine (LDAC)Placebo + Low Dose Cytarabine (LDAC)Total
Median76.0 (36.0 to 93.0)76.0 (41.0 to 88.0)76.0 (36.0 to 93.0)
Age, Customized
Age, Customized(Participants)Venetoclax + Low Dose Cytarabine (LDAC)Placebo + Low Dose Cytarabine (LDAC)Total
18 to < 65 years11920
65 to < 75 years501969
≥ 75 years8240122
Sex: Female, Male
Sex: Female, Male(Participants)Venetoclax + Low Dose Cytarabine (LDAC)Placebo + Low Dose Cytarabine (LDAC)Total
Female652994
Male7839117
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Venetoclax + Low Dose Cytarabine (LDAC)Placebo + Low Dose Cytarabine (LDAC)Total
White10247149
Black or African American213
Asian392059
Region
Region(Participants)Venetoclax + Low Dose Cytarabine (LDAC)Placebo + Low Dose Cytarabine (LDAC)Total
United States13619
European Union562682
China9615
Japan18927
Rest of World472168
AML Status
AML Status(Participants)Venetoclax + Low Dose Cytarabine (LDAC)Placebo + Low Dose Cytarabine (LDAC)Total
De novo8545130
Secondary582381
08

Study locations

109 sites
  • H. Lee Moffit Cancer Center /ID# 164273
    Tampa, Florida 33612, United States
  • Norton Cancer Institute /ID# 158998
    Louisville, Kentucky 40202-3700, United States
  • Univ of Pittsburgh Med Ctr /ID# 158997
    Pittsburgh, Pennsylvania 15232, United States
  • Univ TX, MD Anderson /ID# 159678
    Houston, Texas 77030, United States
  • Swedish Medical Center /ID# 161280
    Seattle, Washington 98104, United States
  • Gundersen Health System /ID# 164272
    La Crosse, Wisconsin 54601, United States
  • Cemic /Id# 159676
    Buenos Aires, 1431, Argentina
  • Sanatorio Allende /ID# 159675
    Córdoba, 5000, Argentina
  • Calvary Mater Newcastle /ID# 160123
    Waratah, New South Wales 2298, Australia
  • Westmead Hospital /ID# 160121
    Westmead, New South Wales 2145, Australia
  • Alfred Hospital /ID# 160125
    Melbourne, Victoria 3004, Australia
  • Box Hill Hospital /ID# 162920
    Melbourne, Victoria 3128, Australia
  • Universitair Ziekenhuis Antwerpen /ID# 159566
    Edegem, Antwerpen 2650, Belgium
  • Cliniques Universitaires Saint Luc /ID# 159567
    Woluwe-Saint-Lambert, Brussels Capital 1200, Belgium
  • Centro de Pesquisas Oncologicas /ID# 163567
    Florianópolis, Santa Catarina 88034-000, Brazil
  • Hospital de Cancer de Barretos /ID# 163568
    Barretos, São Paulo 14784-400, Brazil
  • Casa de Saúde Santa Marcelina /ID# 163413
    São Paulo, São Paulo 08270-070, Brazil
  • Hospital do Cancer Mae de Deus /ID# 163416
    Porto Alegre, 90470-150, Brazil
  • University of Alberta Hospital /ID# 159646
    Edmonton, Alberta T6G 2G3, Canada
  • CISSS de la Monteregie /ID# 159782
    Greenfield Park, Quebec J4V 2H1, Canada
  • Hospital Maisonneuve-Rosemont /ID# 159780
    Montreal, Quebec H1T 2M4, Canada
  • Hopital Sacre Coeur Montreal /ID# 160982
    Montreal, Quebec H4J 1C5, Canada
  • Fujian Medical Univ Union Hosp /ID# 167321
    Fuzhou, Fujian 350001, China
  • Nanfang Hospital of Southern Medical University /ID# 170147
    Guangzhou, Guangdong 510515, China
  • Jiangsu Province People's Hospital /ID# 167511
    Nanjing, Jiangsu 210029, China
  • The First Hosp of Jilin Univ /ID# 167512
    Changchun, Jilin 130021, China
  • Ruijin Hospital, Shanghai Jiaotong /ID# 167325
    Shanghai, Shanghai Municipality 200025, China
  • West China Hospital /ID# 167514
    Chengdu, Sichuan 610041, China
  • Blood disease hosp of Chinese Academy of Med Sciences(Institute of Hematology) /ID# 167509
    Tianjin, Tianjin Municipality 300020, China
  • The First Affiliated Hospital,College of Medicine, Zhejiang University /ID# 167324
    Hangzhou, Zhejiang 310003, China
  • Qilu Hospital of Shandong Univ /ID# 167507
    Jinan, 250014, China
  • Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 167515
    Wuhan, 430022, China
  • Henan Cancer Hospital /ID# 167327
    Zhengzhou, Henan, 450008, China
  • Fakultni Nemocnice Brno /ID# 159247
    Brno, 625 00, Czechia
  • Univ Hosp Ostrava-Poruba /ID# 159246
    Ostrava, 708 52, Czechia
  • Fakult Nem Kralovske Vinohrady /ID# 159248
    Prague, 100 34, Czechia
  • Centre Hospitalier Lyon Sud /ID# 159705
    Pierre-Bénite, Rhone 69495, France
  • Centre Hospitalier Le Mans /ID# 159702
    Le Mans, Sarthe 72037, France
  • Centre Hospitalier de la Cote /ID# 159697
    Bayonne, 64100, France
  • CHU Bordeaux /ID# 159704
    Pessac, 33600, France
  • CHU De Nancy /ID# 159700
    Vandœuvre-lès-Nancy, 54511, France
  • Schwarzwald-Baar-Klinikum /ID# 159571
    Villingen-Schwenningen, Baden-Wurttemberg 78052, Germany
  • Vivantes Klinikum Am Urban /ID# 159569
    Berlin, 10967, Germany
  • Universitaetsklinikum Hamburg /ID# 161760
    Hamburg, 20246, Germany
  • General Hospital of Athens Laiko /ID# 157870
    Athens, Attica 115 27, Greece
  • General Hospital of Thessaloniki George Papanikolaou /ID# 157867
    Thessaloniki, Thessaloniki 57010, Greece
  • Gen Univ Hosp Alexandroupolis /ID# 157868
    Alexandroupoli, 68100, Greece
  • General Hospital of Athens Evaggelismos and Ophthalmiatrio of Athens Polyclinic /ID# 157869
    Athens, 10676, Greece
  • University Gen Hosp of Patra /ID# 157871
    Pátrai, 26504, Greece
  • Dél-pesti Centrumkórház- Országos Hematológiai és Infektológiai Intézet /ID# 159127
    Budapest IX, Budapest 1097, Hungary
  • Pecsi Tudomanyegyetem /ID# 163161
    Pécs, Pecs 7624, Hungary
  • Semmelweis Egyetem I. Belklini /ID# 158180
    Budapest, 1083, Hungary
  • Debreceni Egyetem Klinikai Koz /ID# 158178
    Debrecen, 4032, Hungary
  • Petz Aladar Megyei Oktato Korh /ID# 161739
    Győr, 9023, Hungary
  • Kaposi Mor Oktato Korhaz /ID# 158175
    Kaposvár, 7400, Hungary
  • Bacs-Kiskun Megyei Korhaz /ID# 160973
    Kecskemét, 6000, Hungary
  • St. James's Hospital /ID# 162730
    Dublin, Dublin D08 E9P6, Ireland
  • University Hospital Limerick /ID# 162735
    Limerick, Limerick V94F858, Ireland
  • Beaumont Hospital /ID# 162733
    Dublin, D09 XR63, Ireland
  • University Hospital Galway /ID# 162734
    Galway, H91 YR71, Ireland
  • University of Fukui Hospital /ID# 159770
    Yoshida-gun, Fukui 910-1193, Japan
  • Kyushu University Hospital /ID# 159688
    Fukuoka, Fukuoka 812-8582, Japan
  • Gunmaken Saiseikai Maebashi Hospital /ID# 160597
    Maebashi, Gunma 371-0821, Japan
  • National Hospital Organization Mito Medical Center /ID# 162988
    Higashi Ibaraki-gun, Ibaraki 3113193, Japan
  • Kyoto Prefect Univ Med /ID# 160101
    Kyoto, Kyoto 602-8566, Japan
  • Tohoku University Hospital /ID# 161151
    Sendai, Miyagi 980-8574, Japan
  • Nagasaki University Hospital /ID# 160233
    Nagasaki, Nagasaki 852-8501, Japan
  • Osaka City University Hospital /ID# 159722
    Osaka, Osaka 545-0051, Japan
  • Kinki University -Osakasayama Campus /ID# 160777
    Osakasayama-shi, Osaka 589-8511, Japan
  • Tokyo Metropolitan Komagome Hospital /ID# 160759
    Bunkyo-ku, Tokyo 113-8677, Japan
  • Tokyo Jikei Daisan Hospital /ID# 159769
    Komae-shi, Tokyo 201-8601, Japan
  • NTT Medical Center Tokyo /ID# 160678
    Shinagawa-ku, Tokyo 141-8625, Japan
  • Juntendo University Hospital /ID# 159781
    Tokyo, Tokyo 113-8431, Japan
  • Yamagata University Hospital /ID# 161223
    Yamagata, Yamagata 990-9585, Japan
  • Akita University Hospital /ID# 160602
    Akita, 100041, Japan
  • Saitama Med Univ Int Med Ctr /ID# 161308
    Hidaka, 350-1241, Japan
  • NHO Nagoya Medical Center /ID# 159768
    Nagoya, 460-0001, Japan
  • Dokkyo Medical University Hosp /ID# 159650
    Shimotsuga, 321-0293, Japan
  • Instituto Nacional de Cancerol /ID# 159269
    Mexico City, Mexico City 14080, Mexico
  • Centro de Invest Clin Chapulte /ID# 162625
    Morelia, Michoacán 58260, Mexico
  • Hosp. Univ. Dr. Jose E. Gonz /ID# 159268
    Monterrey, Nuevo León 64320, Mexico
  • Middlemore Clinical Trials /ID# 160131
    Auckland, Auckland 2025, New Zealand
  • North Shore Hospital /ID# 160132
    Auckland, 0622, New Zealand
  • Haukeland University Hospital /ID# 165630
    Bergen, Hordaland 5021, Norway
  • Sykehuset Ostfold Kalnes /ID# 165632
    Grålum, 1714, Norway
  • VA Caribbean Healthcare System /ID# 158999
    San Juan, Puerto Rico 00921-3201, Puerto Rico
  • Kemerovo Regional Clinical Hospital n.a. S.V. Belyaev /ID# 162991
    Kemerovo, Kemerovo Oblast 650066, Russia
  • Nizhniy Novgorod regional clinical hospital named N. A. Semashko /ID# 163186
    Nizhny Novgorod, Nizhny Novgorod Oblast 603126, Russia
  • State Institution of Health of the Ryazan Regional Clinical Hospital /ID# 163126
    Ryazan, Ryazan Oblast 390039, Russia
  • City Clinical Hospital Botkina /ID# 164086
    Moscow, 125284, Russia
  • Almazov North-West Federal Med /ID# 162170
    Saint Petersburg, 197341, Russia
  • Saint Petersburg State Institu /ID# 162171
    Saint Petersburg, 198205, Russia
  • Samara State Medical Universit /ID# 164173
    Samara, 443099, Russia
  • saratov state medical /ID# 163130
    Saratov, 41002, Russia
  • Yaroslavl Regional Clinic Hosp /ID# 162172
    Yaroslavl, 150062, Russia
  • Netcare Pretoria East Hospital /ID# 157373
    Pretoria, Gauteng 0001, South Africa
  • Tshwane District Hospital /ID# 157361
    Pretoria, Gauteng 0001, South Africa
  • Pusan National University Hosp /ID# 158725
    Busan, Busan Gwang Yeogsi 602-739, South Korea
  • Chungnam National University Hospital /ID# 158726
    Junggu, Daejeon Gwang Yeogsi 35015, South Korea
  • Cath Univ Seoul St Mary's Hosp /ID# 158724
    Seoul, Seoul Teugbyeolsi 06591, South Korea

Showing the first 100 of 109 sites across 24 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, Kim I, Stevens DA, Fiedler W, Pagoni M, Samoilova O, Hu Y, Anagnostopoulos A, Bergeron J, Hou JZ, Murthy V, Yamauchi T, McDonald A, Chyla B, Gopalakrishnan S, Jiang Q, Mendes W, Hayslip J, Panayiotidis P. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020 Jun 11;135(24):2137-2145. doi: 10.1182/blood.2020004856. PubMed 32219442 ↗
  • Wei AH, Panayiotidis P, Montesinos P, Laribi K, Ivanov V, Kim I, Novak J, Champion R, Fiedler W, Pagoni M, Bergeron J, Ting SB, Hou JZ, Yamauchi T, Wang J, Strickland SA, Savona MR, Lin TL, Enjeti A, Tiong IS, Lee S, Roboz GJ, Popovic R, Jiang Q, Liu Z, Sun Y, Mendes W, Chyla B, DiNardo CD. Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy. Blood Adv. 2026 Feb 24;10(4):987-998. doi: 10.1182/bloodadvances.2025017083. PubMed 41269778 ↗
  • Badawi M, Chen X, Marroum P, Suleiman AA, Mensing S, Koenigsdorfer A, Schiele JT, Palenski T, Samineni D, Hoffman D, Menon R, Salem AH. Bioavailability Evaluation of Venetoclax Lower-Strength Tablets and Oral Powder Formulations to Establish Interchangeability with the 100 mg Tablet. Clin Drug Investig. 2022 Aug;42(8):657-668. doi: 10.1007/s40261-022-01172-4. Epub 2022 Jul 13. PubMed 35829925 ↗
  • Wei AH, Panayiotidis P, Montesinos P, Laribi K, Ivanov V, Kim I, Novak J, Stevens DA, Fiedler W, Pagoni M, Bergeron J, Ting SB, Hou JZ, Anagnostopoulos A, McDonald A, Murthy V, Yamauchi T, Wang J, Chyla B, Sun Y, Jiang Q, Mendes W, Hayslip J, DiNardo CD. 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy (141/150). Blood Cancer J. 2021 Oct 1;11(10):163. doi: 10.1038/s41408-021-00555-8. PubMed 34599139 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2017 to primary completion in Feb 2019, 20 months.

Results were first posted in Feb 2020, 1 year after primary completion.

Of 43 industry-sponsored phase 3 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 62. This study's 20 months is below that.

Counting every sponsor, half of 121 studies reached it within 74 months; a quarter within 39 and three quarters within 99.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2017
First posted
Mar 3, 2017
StartActual
May 29, 2017
Primary completionActual
Feb 15, 2019
CompletionActual
Aug 21, 2025
Results first posted
Feb 28, 2020
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Posted results revised
revised Oct 16, 2026
Sites
8 sites added, 8 sites removed
Show 8 added (1 Brazil, 1 Greece, 1 Ireland, 1 Japan, 1 New Zealand, 1 Puerto Rico, 1 Spain, 1 United Kingdom)
  • Casa de Saúde Santa Marcelina /ID# 163413 · São Paulo, Brazil
  • General Hospital of Thessaloniki George Papanikolaou /ID# 157867 · Thessaloniki, Greece
  • University Hospital Limerick /ID# 162735 · Limerick, Ireland
  • Juntendo University Hospital /ID# 159781 · Tokyo, Japan
  • Middlemore Clinical Trials /ID# 160131 · Auckland, New Zealand
  • VA Caribbean Healthcare System /ID# 158999 · San Juan, Puerto Rico
  • Hospital Infanta Leonor /ID# 161180 · Madrid, Spain
  • Heartlands Hospital /ID# 163534 · Birmingham, United Kingdom
Show 8 removed
  • Casa de Saúde Santa Marcelina /ID# 163413 · São Paulo, Brazil
  • General Hospital of Thessaloniki George Papanikolaou /ID# 157867 · Thessaloniki, Greece
  • University Hospital Limerick /ID# 162735 · Limerick, Ireland
  • Juntendo University Hospital /ID# 159781 · Tokyo, Japan
  • Middlemore Clinical Trials /ID# 160131 · Auckland, New Zealand
  • VA Caribbean Healthcare System /ID# 158999 · San Juan, Puerto Rico
  • Hospital Infanta Leonor /ID# 161180 · Madrid, Spain
  • Heartlands Hospital /ID# 163534 · Birmingham, United Kingdom
Oct 16, 2026
Start date
May 23, 2017→May 29, 2017
Oct 16, 2026
Documents
Oct 16, 2026
Secondary outcomes
1 edited, 14 time frame changed
What changed in the outcomes
  • EditedChange From Baseline in Global Health Status / Quality of LifeTime frame: Baseline and Day 1 of Cycles 3, 5, 7, and 9 → Baseline and Day 1 of Cycles 3, 5, 7, 9, and 11
  • Time framePercentage of Participants With Complete Remission or Complete Remission With Incomplete Blood Count Recovery (CR + CRi)Response was assessed at the end of Cycle 1 and every 3 cycles thereafter to the end of treatment. Median treatment duration at the 15 February 2019 cut-off date was 1.7 months (range: 0.1-14.2) and 3.9 months (range: 0.0-17.1) in each group respectively. → Response was assessed at the end of Cycle 1 and every 3 cycles thereafter to the end of treatment. Median treatment duration at the 15 August 2019 cut-off date was 1.7 months (range: 0.1-20.2) and 4.1 months (range: 0.0-23.5) in each group respectively.
  • Time framePercentage of Participants With Complete Remission or Complete Remission With Partial Hematologic Recovery (CR + CRh)Response was assessed at the end of Cycle 1 and every 3 cycles thereafter to the end of treatment. Median treatment duration at the 15 February 2019 cut-off date was 1.7 months (range: 0.1-14.2) and 3.9 months (range: 0.0-17.1) in each group respectively. → Response was assessed at the end of Cycle 1 and every 3 cycles thereafter to the end of treatment. Median treatment duration at the 15 August 2019 cut-off date was 1.7 months (range: 0.1-20.2) and 4.1 months (range: 0.0-23.5) in each group respectively.
  • Time framePercentage of Participants With Complete RemissionResponse was assessed at the end of Cycle 1 and every 3 cycles thereafter to the end of treatment. Median treatment duration at the 15 February 2019 cut-off date was 1.7 months (range: 0.1-14.2) and 3.9 months (range: 0.0-17.1) in each group respectively. → Response was assessed at the end of Cycle 1 and every 3 cycles thereafter to the end of treatment. Median treatment duration at the 15 August 2019 cut-off date was 1.7 months (range: 0.1-20.2) and 4.1 months (range: 0.0-23.5) in each group respectively.
  • Time frameChange From Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue Short Form (SF) 7aBaseline and Day 1 of Cycles 3, 5, 7, and 9 → Baseline and Day 1 of Cycles 3, 5, 7, 9, and 11
  • Time frameEvent-free Survival (EFS)From randomization until the primary analysis cut-off date of February 15, 2019; the median follow-up time was 12.0 months (range: 0.2-17.0) in the placebo arm and 12.0 months (range: 0.1-17.6) in the venetoclax arm. → From randomization until the analysis cut-off date of August 15, 2019; the median follow-up time was 17.7 months (range: 0.2 to 20.8) in the placebo arm and 17.5 months (range: 0.1 to 23.5) in the venetoclax arm.
  • Time framePercentage of Participants With Post Baseline Red Blood Cell (RBC) Transfusion IndependenceFrom first dose of study drug until 30 days after last dose up to the data cut-off date of 15 February 2019; Median time on treatment was 1.7 months (range: 0.1-14.2) in the placebo arm and 3.9 months (range: 0.0-17.1) in the venetoclax arm. → From first dose of study drug until 30 days after last dose up to the data cut-off date of 15 August 2019; Median time on treatment was 1.7 months (range: 0.1-20.2) in the placebo arm and 4.1 months (range: 0.0-23.5) in the venetoclax arm.
  • Time framePercentage of Participants With Post Baseline Platelet Transfusion IndependenceFrom first dose of study drug until 30 days after last dose up to the data cut-off date of 15 February 2019; Median time on treatment was 1.7 months (range: 0.1-14.2) in the placebo arm and 3.9 months (range: 0.0-17.1) in the venetoclax arm. → From first dose of study drug until 30 days after last dose up to the data cut-off date of 15 August 2019; Median time on treatment was 1.7 months (range: 0.1-20.2) in the placebo arm and 4.1 months (range: 0.0-23.5) in the venetoclax arm.
  • Time framePercentage of Participants With RBC Transfusion Independence Among Those Who Were Transfusion Dependent at BaselineFrom first dose of study drug until 30 days after last dose up to the data cut-off date of 15 February 2019; Median time on treatment was 1.7 months (range: 0.1-14.2) in the placebo arm and 3.9 months (range: 0.0-17.1) in the venetoclax arm. → From first dose of study drug until 30 days after last dose up to the data cut-off date of 15 August 2019; Median time on treatment was 1.7 months (range: 0.1-20.2) in the placebo arm and 4.1 months (range: 0.0-23.5) in the venetoclax arm.
  • Time framePercentage of Participants With Platelet Transfusion Independence Among Those Who Were Transfusion Dependent at BaselineFrom first dose of study drug until 30 days after last dose up to the data cut-off date of 15 February 2019; Median time on treatment was 1.7 months (range: 0.1-14.2) in the placebo arm and 3.9 months (range: 0.0-17.1) in the venetoclax arm. → From first dose of study drug until 30 days after last dose up to the data cut-off date of 15 August 2019; Median time on treatment was 1.7 months (range: 0.1-20.2) in the placebo arm and 4.1 months (range: 0.0-23.5) in the venetoclax arm.
  • Time framePercentage of Participants With Complete Remission or Complete Remission With Incomplete Blood Count Recovery (CR + CRi) and Minimal Residual Disease (MRD) ResponseResponse was assessed at the end of Cycle 1 and every 3 cycles thereafter to the end of treatment. Median treatment duration at the 15 February 2019 cut-off date was 1.7 months (range: 0.1-14.2) and 3.9 months (range: 0.0-17.1) in each group respectively. → Response was assessed at the end of Cycle 1 and every 3 cycles thereafter to the end of treatment. Median treatment duration at the 15 August 2019 cut-off date was 1.7 months (range: 0.1-20.2) and 4.1 months (range: 0.0-23.5) in each group respectively.
  • Time framePercentage of Participants With Complete Remission or Complete Remission With Partial Hematologic Recovery (CR + CRh) and Minimal Residual Disease (MRD) ResponseResponse was assessed at the end of Cycle 1 and every 3 cycles thereafter to the end of treatment. Median treatment duration at the 15 February 2019 cut-off date was 1.7 months (range: 0.1-14.2) and 3.9 months (range: 0.0-17.1) in each group respectively. → Response was assessed at the end of Cycle 1 and every 3 cycles thereafter to the end of treatment. Median treatment duration at the 15 August 2019 cut-off date was 1.7 months (range: 0.1-20.2) and 4.1 months (range: 0.0-23.5) in each group respectively.
  • Time frameOverall Survival (OS) by Mutation SubgroupsFrom randomization until the primary analysis cut-off date of February 15, 2019; the median follow-up time was 12.0 months (range: 0.2-17.0) in the placebo arm and 12.0 months (range: 0.1-17.6) in the venetoclax arm. → From randomization until the analysis cut-off date of August 15, 2019; the median follow-up time was 17.7 months (range: 0.2 to 20.8) in the placebo arm and 17.5 months (range: 0.1 to 23.5) in the venetoclax arm.
  • Time framePercentage of Participants With Complete Remission or Complete Remission With Incomplete Blood Count Recovery (CR + CRi) by Mutation SubgroupResponse was assessed at the end of Cycle 1 and every 3 cycles thereafter to the end of treatment. Median treatment duration at the 15 February 2019 cut-off date was 1.7 months (range: 0.1-14.2) and 3.9 months (range: 0.0-17.1) in each group respectively. → Response was assessed at the end of Cycle 1 and every 3 cycles thereafter to the end of treatment. Median treatment duration at the 15 August 2019 cut-off date was 1.7 months (range: 0.1-20.2) and 4.1 months (range: 0.0-23.5) in each group respectively.
  • Time framePercentage of Participants With Complete Remission or Complete Remission With Partial Hematologic Recovery (CR + CRh) by Mutation SubgroupResponse was assessed at the end of Cycle 1 and every 3 cycles thereafter to the end of treatment. Median treatment duration at the 15 February 2019 cut-off date was 1.7 months (range: 0.1-14.2) and 3.9 months (range: 0.0-17.1) in each group respectively. → Response was assessed at the end of Cycle 1 and every 3 cycles thereafter to the end of treatment. Median treatment duration at the 15 August 2019 cut-off date was 1.7 months (range: 0.1-20.2) and 4.1 months (range: 0.0-23.5) in each group respectively.
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Posted results revised
    Documents Study protocol ↗ updated
    8 sites added, 8 sites removed
    Show 8 added (1 Brazil, 1 Greece, 1 Ireland, 1 Japan, 1 New Zealand, 1 Puerto Rico, 1 Spain, 1 United Kingdom)
    • Casa de Saúde Santa Marcelina /ID# 163413 · São Paulo, Brazil
    • General Hospital of Thessaloniki George Papanikolaou /ID# 157867 · Thessaloniki, Greece
    • University Hospital Limerick /ID# 162735 · Limerick, Ireland
    • Juntendo University Hospital /ID# 159781 · Tokyo, Japan
    • Middlemore Clinical Trials /ID# 160131 · Auckland, New Zealand
    • VA Caribbean Healthcare System /ID# 158999 · San Juan, Puerto Rico
    • Hospital Infanta Leonor /ID# 161180 · Madrid, Spain
    • Heartlands Hospital /ID# 163534 · Birmingham, United Kingdom
    Show 8 removed
    • Casa de Saúde Santa Marcelina /ID# 163413 · São Paulo, Brazil
    • General Hospital of Thessaloniki George Papanikolaou /ID# 157867 · Thessaloniki, Greece
    • University Hospital Limerick /ID# 162735 · Limerick, Ireland
    • Juntendo University Hospital /ID# 159781 · Tokyo, Japan
    • Middlemore Clinical Trials /ID# 160131 · Auckland, New Zealand
    • VA Caribbean Healthcare System /ID# 158999 · San Juan, Puerto Rico
    • Hospital Infanta Leonor /ID# 161180 · Madrid, Spain
    • Heartlands Hospital /ID# 163534 · Birmingham, United Kingdom
    Start date May 23, 2017→May 29, 2017
    Secondary outcomes 1 edited, 14 time frame changed
    What changed in the outcomes
    • EditedChange From Baseline in Global Health Status / Quality of LifeTime frame: Baseline and Day 1 of Cycles 3, 5, 7, and 9 → Baseline and Day 1 of Cycles 3, 5, 7, 9, and 11
    • Time framePercentage of Participants With Complete Remission or Complete Remission With Incomplete Blood Count Recovery (CR + CRi)Response was assessed at the end of Cycle 1 and every 3 cycles thereafter to the end of treatment. Median treatment duration at the 15 February 2019 cut-off date was 1.7 months (range: 0.1-14.2) and 3.9 months (range: 0.0-17.1) in each group respectively. → Response was assessed at the end of Cycle 1 and every 3 cycles thereafter to the end of treatment. Median treatment duration at the 15 August 2019 cut-off date was 1.7 months (range: 0.1-20.2) and 4.1 months (range: 0.0-23.5) in each group respectively.
    • Time framePercentage of Participants With Complete Remission or Complete Remission With Partial Hematologic Recovery (CR + CRh)Response was assessed at the end of Cycle 1 and every 3 cycles thereafter to the end of treatment. Median treatment duration at the 15 February 2019 cut-off date was 1.7 months (range: 0.1-14.2) and 3.9 months (range: 0.0-17.1) in each group respectively. → Response was assessed at the end of Cycle 1 and every 3 cycles thereafter to the end of treatment. Median treatment duration at the 15 August 2019 cut-off date was 1.7 months (range: 0.1-20.2) and 4.1 months (range: 0.0-23.5) in each group respectively.
    • Time framePercentage of Participants With Complete RemissionResponse was assessed at the end of Cycle 1 and every 3 cycles thereafter to the end of treatment. Median treatment duration at the 15 February 2019 cut-off date was 1.7 months (range: 0.1-14.2) and 3.9 months (range: 0.0-17.1) in each group respectively. → Response was assessed at the end of Cycle 1 and every 3 cycles thereafter to the end of treatment. Median treatment duration at the 15 August 2019 cut-off date was 1.7 months (range: 0.1-20.2) and 4.1 months (range: 0.0-23.5) in each group respectively.
    • Time frameChange From Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue Short Form (SF) 7aBaseline and Day 1 of Cycles 3, 5, 7, and 9 → Baseline and Day 1 of Cycles 3, 5, 7, 9, and 11
    • Time frameEvent-free Survival (EFS)From randomization until the primary analysis cut-off date of February 15, 2019; the median follow-up time was 12.0 months (range: 0.2-17.0) in the placebo arm and 12.0 months (range: 0.1-17.6) in the venetoclax arm. → From randomization until the analysis cut-off date of August 15, 2019; the median follow-up time was 17.7 months (range: 0.2 to 20.8) in the placebo arm and 17.5 months (range: 0.1 to 23.5) in the venetoclax arm.
    • Time framePercentage of Participants With Post Baseline Red Blood Cell (RBC) Transfusion IndependenceFrom first dose of study drug until 30 days after last dose up to the data cut-off date of 15 February 2019; Median time on treatment was 1.7 months (range: 0.1-14.2) in the placebo arm and 3.9 months (range: 0.0-17.1) in the venetoclax arm. → From first dose of study drug until 30 days after last dose up to the data cut-off date of 15 August 2019; Median time on treatment was 1.7 months (range: 0.1-20.2) in the placebo arm and 4.1 months (range: 0.0-23.5) in the venetoclax arm.
    • Time framePercentage of Participants With Post Baseline Platelet Transfusion IndependenceFrom first dose of study drug until 30 days after last dose up to the data cut-off date of 15 February 2019; Median time on treatment was 1.7 months (range: 0.1-14.2) in the placebo arm and 3.9 months (range: 0.0-17.1) in the venetoclax arm. → From first dose of study drug until 30 days after last dose up to the data cut-off date of 15 August 2019; Median time on treatment was 1.7 months (range: 0.1-20.2) in the placebo arm and 4.1 months (range: 0.0-23.5) in the venetoclax arm.
    • Time framePercentage of Participants With RBC Transfusion Independence Among Those Who Were Transfusion Dependent at BaselineFrom first dose of study drug until 30 days after last dose up to the data cut-off date of 15 February 2019; Median time on treatment was 1.7 months (range: 0.1-14.2) in the placebo arm and 3.9 months (range: 0.0-17.1) in the venetoclax arm. → From first dose of study drug until 30 days after last dose up to the data cut-off date of 15 August 2019; Median time on treatment was 1.7 months (range: 0.1-20.2) in the placebo arm and 4.1 months (range: 0.0-23.5) in the venetoclax arm.
    • Time framePercentage of Participants With Platelet Transfusion Independence Among Those Who Were Transfusion Dependent at BaselineFrom first dose of study drug until 30 days after last dose up to the data cut-off date of 15 February 2019; Median time on treatment was 1.7 months (range: 0.1-14.2) in the placebo arm and 3.9 months (range: 0.0-17.1) in the venetoclax arm. → From first dose of study drug until 30 days after last dose up to the data cut-off date of 15 August 2019; Median time on treatment was 1.7 months (range: 0.1-20.2) in the placebo arm and 4.1 months (range: 0.0-23.5) in the venetoclax arm.
    • Time framePercentage of Participants With Complete Remission or Complete Remission With Incomplete Blood Count Recovery (CR + CRi) and Minimal Residual Disease (MRD) ResponseResponse was assessed at the end of Cycle 1 and every 3 cycles thereafter to the end of treatment. Median treatment duration at the 15 February 2019 cut-off date was 1.7 months (range: 0.1-14.2) and 3.9 months (range: 0.0-17.1) in each group respectively. → Response was assessed at the end of Cycle 1 and every 3 cycles thereafter to the end of treatment. Median treatment duration at the 15 August 2019 cut-off date was 1.7 months (range: 0.1-20.2) and 4.1 months (range: 0.0-23.5) in each group respectively.
    • Time framePercentage of Participants With Complete Remission or Complete Remission With Partial Hematologic Recovery (CR + CRh) and Minimal Residual Disease (MRD) ResponseResponse was assessed at the end of Cycle 1 and every 3 cycles thereafter to the end of treatment. Median treatment duration at the 15 February 2019 cut-off date was 1.7 months (range: 0.1-14.2) and 3.9 months (range: 0.0-17.1) in each group respectively. → Response was assessed at the end of Cycle 1 and every 3 cycles thereafter to the end of treatment. Median treatment duration at the 15 August 2019 cut-off date was 1.7 months (range: 0.1-20.2) and 4.1 months (range: 0.0-23.5) in each group respectively.
    • Time frameOverall Survival (OS) by Mutation SubgroupsFrom randomization until the primary analysis cut-off date of February 15, 2019; the median follow-up time was 12.0 months (range: 0.2-17.0) in the placebo arm and 12.0 months (range: 0.1-17.6) in the venetoclax arm. → From randomization until the analysis cut-off date of August 15, 2019; the median follow-up time was 17.7 months (range: 0.2 to 20.8) in the placebo arm and 17.5 months (range: 0.1 to 23.5) in the venetoclax arm.
    • Time framePercentage of Participants With Complete Remission or Complete Remission With Incomplete Blood Count Recovery (CR + CRi) by Mutation SubgroupResponse was assessed at the end of Cycle 1 and every 3 cycles thereafter to the end of treatment. Median treatment duration at the 15 February 2019 cut-off date was 1.7 months (range: 0.1-14.2) and 3.9 months (range: 0.0-17.1) in each group respectively. → Response was assessed at the end of Cycle 1 and every 3 cycles thereafter to the end of treatment. Median treatment duration at the 15 August 2019 cut-off date was 1.7 months (range: 0.1-20.2) and 4.1 months (range: 0.0-23.5) in each group respectively.
    • Time framePercentage of Participants With Complete Remission or Complete Remission With Partial Hematologic Recovery (CR + CRh) by Mutation SubgroupResponse was assessed at the end of Cycle 1 and every 3 cycles thereafter to the end of treatment. Median treatment duration at the 15 February 2019 cut-off date was 1.7 months (range: 0.1-14.2) and 3.9 months (range: 0.0-17.1) in each group respectively. → Response was assessed at the end of Cycle 1 and every 3 cycles thereafter to the end of treatment. Median treatment duration at the 15 August 2019 cut-off date was 1.7 months (range: 0.1-20.2) and 4.1 months (range: 0.0-23.5) in each group respectively.
    + 3 other changes: identifiers, verification date and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03069352
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Mar 3, 2017
Start date
May 29, 2017
Primary completion
Feb 15, 2019
Completion
Aug 21, 2025
Results posted
Feb 28, 2020
Last update
Oct 16, 2026

Study contacts

AbbVie Inc.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Venetoclax

Start the discussion